NNVC Latest Press Releases

-- April 21, 2026 --

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides ACCESS Newswire 8:30 AM

-- April 7, 2026 --

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides ACCESS Newswire 8:30 AM

-- April 1, 2026 --

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides ACCESS Newswire 8:30 AM

-- March 11, 2026 --

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete ACCESS Newswire 8:30 AM

-- February 12, 2026 --

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides ACCESS Newswire 8:30 AM

-- February 10, 2026 --

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides ACCESS Newswire 8:30 AM

-- February 2, 2026 --

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres ACCESS Newswire 8:30 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software